SGLT2 Inhibitors Begin to Show Potential in Rheumatology SGLT2 Inhibitors Begin to Show Potential in Rheumatology

Sodium-glucose cotransporter-2 inhibitors are not approved to treat gout, lupus, or lupus nephritis, but clinicians are uncovering signs of benefits in these conditions.MDedge News

Source: Medscape Diabetes Headlines - January 8, 2024 Category: Endocrinology Tags: Rheumatology Source Type: news